NextCure, Inc. (NXTC) – Finance Report
Company Overview
NextCure, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel immunomedicines to treat cancer and other immune-related diseases. The company is focused on restoring normal immune function through its immunomedicines. NextCure is headquartered in Beltsville, Maryland and was incorporated in 2015.
Financial Performance
- Market Cap: $55.5 million
- Previous Close: $1.99
- Open: $1.95
- Day Range: $1.94 – $2.04
- 52-Week Range: $0.98 – $2.09
- Average Volume: 233,837
- Shares Outstanding: 27,903,000
- Trailing P/E Ratio: -2.23
- Forward P/E Ratio: -1.68
Recent Developments
- NextCure is currently focused on the development of three immunomedicines. These include NC410, which is designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells.
- The company has a strong research and development program, with a pipeline of potential novel immunomodulatory molecules in preclinical evaluation.
- NextCure has a license agreement with Yale University, which provides the company with access to cutting-edge research and technology.
- The company's executive team is led by CEO and President, Mr. Michael S. Richman, who has over 30 years of experience in the biopharmaceutical industry.
Financial Analysis
- NextCure's financial performance has been mixed. The company reported a net loss of $62.7 million in the last fiscal year, resulting in a negative trailing EPS of -$2.23.
- The company's forward PE ratio is -1.68, indicating that analysts expect the company to continue reporting losses in the near future.
- NextCure has a strong cash position, with a total cash balance of $108.3 million. This provides the company with the necessary resources to fund its research and development programs.
- The company has a debt-to-equity ratio of 5.773, indicating a moderate level of debt.
Stock Price Prediction
- The stock has a 52-week high of $2.09 and a 52-week low of $0.98. The current stock price is $1.97.
- Analysts have a mean price target of $5.00 for NextCure, indicating a potential upside of approximately 153% from the current stock price.
- The stock has a recommendation rating of "Buy" based on the consensus of three analysts.
Conclusion
NextCure is a clinical-stage biopharmaceutical company focused on the development of novel immunomedicines to treat cancer and other immune-related diseases. The company has a strong research and development program and a promising pipeline of potential immunomodulatory molecules. While the company has reported losses in recent years, it has a strong cash position to fund its operations. Analysts have a positive outlook for the stock, with a mean price target of $5.00. However, as with any biopharmaceutical company, there are inherent risks associated with drug development and regulatory approval. Investors should carefully consider these risks before making investment decisions.
